Phibro animal health director sells $765k in shares

Jack Bendheim, a director at Phibro Animal Health Corp (NASDAQ:PAHC), and BFI Co., LLC, a ten percent owner, sold a combined total of 18,899 shares of Class A Common Stock in multiple transactions between October 22 and October 24, 2025. The sales come as PAHC trades near its 52-week high of $41.57, with the stock showing remarkable momentum, gaining over 122% in the past six months. The sales amounted to approximately $765,941, with prices ranging from $40.1796 to $41.749 per share.

The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.

Specifically, on October 22, 11,859 shares were sold at a weighted average price of $40.2692, with individual prices ranging from $40.00 to $41.555. On October 23, 3,520 shares were sold at a weighted average price of $40.1796, with prices ranging from $40.00 to $40.46. A further 3,520 shares were sold on October 24 at a weighted average price of $41.749, with prices ranging from $41.265 to $42.28.

Following these transactions, BFI Co., LLC directly holds 55,000 shares. Jack Bendheim may be deemed to have shared voting and investment power over these securities. Bendheim also directly holds 16,840 shares. For deeper insights into insider trading patterns and comprehensive valuation analysis, InvestingPro subscribers can access detailed research reports covering 1,400+ US stocks, including PAHC.

In other recent news, Phibro Animal Health Corporation reported stronger-than-expected financial results for the fourth quarter of 2025. The company’s earnings per share (EPS) came in at $0.57, surpassing analyst forecasts of $0.52, resulting in a 9.62% surprise. Additionally, revenue exceeded expectations, reaching $378.7 million compared to the projected $362.24 million. In a strategic move, Phibro secured exclusive worldwide rights to a novel canine periodontal therapy through a licensing agreement with Lighthouse Pharmaceuticals, Inc. This compound has shown promising results in preclinical testing. BNP Paribas Exane raised its price target for Phibro to $37 from $24, maintaining a Neutral rating following the company’s earnings beat and strong fiscal 2026 guidance. The research firm noted the company’s recent revenue growth and margin expansion momentum. These developments highlight Phibro’s ongoing strategic initiatives and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.